Here is a breakdown of the information Valneva Se presented to its investors. Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for ...

Valneva (VALN) has released an update. Valneva SE has reported €116.6 million in total revenues for the first nine months of 2024, with a notable turnaround to a €24.7 million net profit, driven by ...

Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 ...

Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics. The French pharma company ...

New data for Valneva and Pfizer's experimental vaccine for Lyme disease – the furthest ahead in clinical testing – have bolstered the case for the shot as the results of a phase 3 programme ...

The global sales of attenuated vaccines are projected to soar, with an estimated worth of USD 5,068.2 million in 2024 and anticipated to reach USD 9,693.9 million by 2034. This growth trajectory ...

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Inactivated vaccines, also called killed vaccines, are made from a protein or other small pieces taken from a virus or bacteria. They use this component to stimulate the immune system to protect the ...

Eliminating fake vaccine news with pharmacist, nurse, and physician review.

This includes not only the flu shot but also pneumonia vaccines, shingles vaccines, and COVID-19 vaccinations and boosters. These preventative measures can protect against severe illnesses and ...